As our post-Levine
preemption cheat sheet demonstrates,
Mensing/Bartlett preemption is breathing down the
necks of all prescription drug design defect claims. Recent cases
finding preemption of design defect claims due to the need for FDA
pre-approval of "major" or "moderate" design
changes (basically, anything that could be causal in a product
liability lawsuit) include: Yates v. Ortho-McNeil
Pharmaceuticals, Inc., 808 F.3d 281, 298 (6th Cir. 2015);
Young v. Bristol-Myers Squibb Co., 2017 WL 706320, at *5
(N.D. Miss. Feb. 22, 2017); Utts v. Bristol-Myers Squibb
Co., ___ F. Supp.3d ___, 2016 WL 7429449, at *12 (S.D.N.Y.
Dec. 23, 2016); Brazil v. Janssen Research & Development
LLC, 196 F. Supp.3d 1351, 1364 (N.D. Ga. 2016); Fleming v.
Janssen Pharmaceuticals, Inc., 186 F. Supp.3d 826, 832-34
(W.D. Tenn. 2016); Batoh v. McNeil-PPC, Inc., 167 F.
Supp.3d 296, 320-22 (D. Conn. 2016) (OTC drug); Barcal v. EMD
Serono, Inc., 2016 WL 1086028, at *4 (N.D. Ala. March
